Brief: Cymabay Completes Enrollment For Response Global Phase 3 Study Evaluating Seladelpar For Patients With Primary Biliary Cholangitis
01/08/2022 14:42
Aug 1 (Reuters) - Cymabay Therapeutics Inc CBAY.O :
* CYMABAY COMPLETES ENROLLMENT FOR RESPONSE GLOBAL PHASE 3
STUDY
EVALUATING SELADELPAR FOR PATIENTS WITH PRIMARY BILIARY
CHOLANGITIS
Source text for Eikon: ID:nGNX1wgtKF
Further company coverage: CBAY.O
((Reuters.Briefs@thomsonreuters.com;))
Recent news on CymaBay Therapeutics
See all newsBrief: CymaBay Says EMA Accepted For Review The Marketing Authorization Application For Seladelpar
U.S. RESEARCH ROUNDUP-Bruker Corp, Cymabay Therapeutics, SSR Mining
U.S. RESEARCH ROUNDUP-An2 Therapeutics, Par Technology, Trimble
U.S. STOCKS ON THE MOVE-Perpetua Resources, Nvidia, SiriusXM
U.S. STOCKS ON THE MOVE-Lowe's, Bit Digital Snap